Akuamma (Picralima nitida) — properties, dosage, and safety
Akuamma—what it is, how it works, and what it helps with. A clear guide from Bucha.
Akuamma is an herb from West Africa that is just beginning to enter the broader awareness of European plant users. The seeds of the tree Picralima nitida have been used in traditional medicine in Ghana, Nigeria, and Cameroon for centuries as a pain reliever and antipyretic. Scientific research confirms that the main alkaloid — akuammicine — binds to opioid receptors. The growing interest in this herb as an alternative to synthetic opioids makes it worth getting to know it thoroughly: what we know about it, what we don't know, and what to watch out for.
KEY INFORMATION
• Akuammicine, the main alkaloid of akuamma, shows affinity for kappa and mu opioid receptors — this explains its traditional pain-relieving use (Menzies et al., Journal of Natural Products, 1995).
• There is a lack of randomized clinical trials on humans — all knowledge comes from in vitro studies, animal models, and traditional use.
• EMCDDA monitors akuamma as an opioid-like substance requiring observation (2021 report).
• In Poland, in 2026, akuamma is not a controlled substance — although its status may change.
• Do not combine akuamma with other substances acting on the opioid system — additive risk, not clinically studied.
What is akuamma — botany and history
Picralima nitida is a tropical tree of the Apocynaceae family, found in humid equatorial forests from Senegal through Nigeria to Uganda. It grows up to 35 meters tall and produces large, yellow fruits containing 2 to 8 seeds. The seeds—called "akuamma seeds" in the trade—are dried, ground, and used in traditional African medicine (Menzies et al., Journal of Natural Products, 1995).
In Ghanaian medicine, akuamma seeds were used to treat pain, fever, malaria, and diarrhea. Seed powder was mixed with water or palm wine and administered orally. The bark and leaves of the tree were used externally, including for joint and muscle pain. In Nigeria, akuamma is known as "Mbom" and in Ghana as "Alamu.".
Akuamma arrived in Europe and North America as a botanical alternative to kratom (Mitragyna speciosa), another Asian herb with a similar, opioid-like mechanism of action. Growing interest in "natural alternatives to opioids" led to akuamma appearing on botanical markets between 2010 and 2020. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has listed akuamma in its Early Warning Reports as a substance requiring monitoring.
Akuammicine alkaloid — mechanism of action
The main alkaloid of akuamma is akuammicin (pisscidia, akuammin) — an indole alkaloid from the corynane group, closely related structurally to ajmaline and mitragynine (kratom alkaloid). In vitro studies from 1995 showed that akuammicin binds to kappa (κ) and mu (μ) opioid receptors with Ki values in the range similar to morphine, but has weaker agonist activity — which theoretically suggests a milder, "partial" opioid effect (Menzies et al., Journal of Natural Products, 1995).
In addition to akuammicine, other alkaloids are present in the seeds: pericine, akuamidine, pseudo-akuammicine, and strictamine. Each of them may exhibit its own biological activity. Interactions between them (the entourage effect analogous to cannabis) have not yet been studied. This means that the effect of the whole seed extract may differ from that of isolated akuammicine — an open question without clinical data.
It is interesting to compare akuammicine to mitragynine (kratom) in terms of binding to opioid receptors. Both compounds show affinity for the mu receptor, but akuammicine exhibits relatively higher affinity for the kappa receptor. Kappa receptors are responsible for different effects than mu — sedative, dysphoric, and hallucinogenic effects at higher doses. This distinction may be important when assessing the action profile and risks of both substances.
Table of properties, dosage, and safety of akuamma
The table below summarizes available information about akuamma in one place. Due to the lack of human clinical trials, many of the cells contain data from traditional use or animal models—this is noted. Data from "clinical trials" refers only to data based on human studies.
| Aspect | Data / description | Source |
|---|---|---|
| Main alkaloid | Akuammicine (+ pericine, akuamidine) | Menzies et al., 1995 |
| Target receptors | Opioid μ and κ (in vitro) | Menzies et al., 1995 |
| Traditional dose | 1-2 seeds (approx. 200-400 mg of powder) | Ethnomedical tradition |
| Duration of action | 2-4 hours (according to users) | Anecdotal data |
| Clinical studies on humans | No RCT | EMCDDA, 2021 |
| Analgesic effect | Confirmed in vitro and in animal models | Menzies et al., 1995 |
| Antipyretic effect | Traditional use; no clinical data | Ethnomedicine |
| Addiction potential | Theoretical (opioid mechanism); clinically unstudied | EMCDDA, 2021 |
| Legal status PL (2026) | Legal — not on the list of controlled substances | Act on counteracting drug addiction Dz.U. 2023 |
| Critical interactions | Opioids, benzodiazepines, alcohol, CNS depressant medications | Theoretical, based on mechanism |
Akuamma and kratom — comparison of two opioid-like plants
Akuamma and kratom (Mitragyna speciosa) are two plants from different continents that have fallen into the common market segment of "natural opioid-like substances." Kratom originates from Southeast Asia and is better researched, with several clinical trials (though no high-quality RCTs) and a more extensive documentation of adverse event cases. Akuamma is much less researched and has a shorter history in the Western market.
The main chemical difference: mitragynine (kratom) acts more strongly on the mu receptor, while akuammicine (akuamma) shows proportionally higher affinity for the kappa receptor. Kappa receptors are responsible for different effects than mu — sedation, dysphoria at higher doses, and potentially a weaker physical addiction potential than full mu agonists. However, this is a hypothesis, not a proven clinical fact.
Effect profile according to users (anecdotal, non-clinical data): Akuamma is described as "milder and shorter" than kratom—the effect lasts 2-3 hours vs. 3-6 hours for kratom. Kratom users sometimes use Akuamma as a substitute for accessibility issues or as a "milder alternative." There is no clinical data supporting the safety or effectiveness of such use—any such decision is an untested experiment.
Safety — what we know, what we don't know
A fair assessment of akuamma's safety must start with the acknowledgment: there is a lack of randomized clinical trials on humans. All safety data regarding humans comes from case reports, user reports, and analogies to other opioid-like substances. This does not mean that akuamma is unsafe — it means that we do not have sufficient data for a reliable safety profile assessment.
What do we know from in vitro studies and animal models? Akuammicine has shown activity on the central nervous system (CNS) at doses comparable to morphine, although with lower efficacy. Toxicological studies on rodents did not show acute toxicity at doses several times higher than those traditionally used by humans. This is a positive sign, but it does not directly translate to a safety assessment for humans with chronic use.
Critical interactions to avoid: other substances acting on opioid receptors (synthetic opioids, kratom, poppy seed tea), benzodiazepines, and other drugs that depress the CNS, alcohol in combination with higher doses. These combinations can lead to additive respiratory suppression — a life-threatening effect. Never combine akuamma with any of these substances.
On online forums dedicated to ethnomedicinal herbs, akuamma regularly appears in discussions about "natural alternatives to kratom." Users report milder and shorter-lasting effects than kratom, often describing it as "gentler." However, it's important to remember that user reports are not a substitute for clinical trials—placebo and expectation bias can strongly influence subjective experiences with psychoactive substances.
Frequently Asked Questions
What is akuamma and where does it come from?
Akuamma is the common name for the seeds of a tree Picralima nitida from the Apocynaceae family, growing in the tropical forests of West and Central Africa. In traditional Ghanaian and Nigerian medicine, they have been used as a pain reliever, antipyretic, and antimalarial. The main alkaloids are akuammicine and pericine, which show affinity for opioid receptors (Menzies et al., Journal of Natural Products, 1995).
How does akuamma work for pain?
Akuammicine binds to kappa (κ) and mu (μ) opioid receptors. In vitro studies have shown comparable affinity to morphine, but weaker agonistic activity — suggesting potential analgesic effects with a lower risk of strong opioid effects (Menzies et al., Journal of Natural Products, 1995). However, there is a lack of randomized clinical trials on humans that would confirm these effects.
What is the safe dose of akuamma?
No official safe dose for humans has been established — there is a lack of clinical studies. Traditionally, 1-2 seeds (about 200-400 mg of powder) have been used per dose. Due to the lack of data and potential effects on the opioid system, akuamma should be used cautiously, in low doses, without combining it with other substances affecting the CNS.
Does akuamma cause addiction?
The potential for akuamma addiction has not been clinically studied. As a substance acting on opioid receptors, it carries a theoretical risk of addiction with regular use. EMCDDA monitors akuamma as an opioid-like substance requiring observation (2021). Regular, daily use without breaks is discouraged due to this risk.
Is akuamma legal in Poland?
In 2026, akuamma (Picralima nitida) and its alkaloid akuammicine are not listed on the Polish controlled substances list (Act on Counteracting Drug Addiction, Journal of Laws of 2023). Akuamma is legally available as a botanical product. However, the growing interest in opioid-like substances may prompt regulators to review the list — always verify the current legal status before purchasing.
This article is for informational and educational purposes and does not replace consultation with a doctor. If you are pregnant, breastfeeding, taking medications, or have chronic conditions, consult the use of supplements or herbs with a specialist.
Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04
